应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01177 中国生物制药
已收盘 07-22 16:08:56
2.890
+0.040
+1.40%
最高
2.900
最低
2.840
成交量
1,865万
今开
2.860
昨收
2.850
日振幅
2.11%
总市值
543.07亿
流通市值
543.07亿
总股本
187.91亿
成交额
5,369万
换手率
0.10%
流通股本
187.91亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
中国生物制药07月22日主力资金流入854万元 连续5日加仓
自选股智能写手 · 16:16
中国生物制药07月22日主力资金流入854万元 连续5日加仓
【港股通】中国生物制药(01177)ESG表现获标普全球、富时罗素等多家权威机构认可
金吾财讯 · 07-19
【港股通】中国生物制药(01177)ESG表现获标普全球、富时罗素等多家权威机构认可
中国生物制药(01177.HK):ESG表现获得标普全球、富时罗素认可
格隆汇资讯 · 07-19
中国生物制药(01177.HK):ESG表现获得标普全球、富时罗素认可
中国生物制药(01177.HK)1类创新药库莫西利胶囊的新药上市申请获受理
港股解码 · 07-18
中国生物制药(01177.HK)1类创新药库莫西利胶囊的新药上市申请获受理
中国生物制药(01177):1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”新药上市申请获得受理
智通财经 · 07-18
中国生物制药(01177):1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”新药上市申请获得受理
中国生物制药07月18日主力资金流入1901万元 连续3日加仓
自选股智能写手 · 07-18
中国生物制药07月18日主力资金流入1901万元 连续3日加仓
中国生物制药(01177)出现大手买入200万股,成交价$2.95,涉资590万
阿斯达克财经 · 07-17
中国生物制药(01177)出现大手买入200万股,成交价$2.95,涉资590万
中国生物制药(01177)上涨5.32%,报2.97元/股
金融界 · 07-17
中国生物制药(01177)上涨5.32%,报2.97元/股
中国生物制药盘中异动 急速拉升5.32%
自选股智能写手 · 07-17
中国生物制药盘中异动 急速拉升5.32%
港股异动 | 中国生物制药(01177)涨近5% 创新产品正密集上市 上半年业绩增速复苏确定性高
智通财经 · 07-17
港股异动 | 中国生物制药(01177)涨近5% 创新产品正密集上市 上半年业绩增速复苏确定性高
中国生物制药(01177):盐酸安罗替尼胶囊联合化疗用于晚期软组织肉瘤一线治疗III期研究取得阳性结果
智通财经网 · 07-16
中国生物制药(01177):盐酸安罗替尼胶囊联合化疗用于晚期软组织肉瘤一线治疗III期研究取得阳性结果
中国生物制药(01177)出现大手买入75.2万股,成交价$2.82,涉资212.064万
阿斯达克财经 · 07-16
中国生物制药(01177)出现大手买入75.2万股,成交价$2.82,涉资212.064万
【港股通】中国生物制药(01177)反复涨超2% 交银指其上半年业绩增速复苏确定性高
金吾财讯 · 07-16
【港股通】中国生物制药(01177)反复涨超2% 交银指其上半年业绩增速复苏确定性高
中国生物制药(01177)出现大手买入96.8万股,成交价$2.81,涉资272.008万
阿斯达克财经 · 07-16
中国生物制药(01177)出现大手买入96.8万股,成交价$2.81,涉资272.008万
智通港股早知道 | 美联储对通胀达标的信心有所增强 TCL电子(01070)发盈喜
智通财经 · 07-16
智通港股早知道 | 美联储对通胀达标的信心有所增强 TCL电子(01070)发盈喜
中生制药(01177.HK)创新药罗伐昔替尼片获国家药监局受理新药上市申请
阿斯达克财经 · 07-15
中生制药(01177.HK)创新药罗伐昔替尼片获国家药监局受理新药上市申请
中国生物制药(01177):1类创新药罗伐昔替尼片“Rovadicitinib(TQ05105)”新药上市申请获得受理
智通财经网 · 07-15
中国生物制药(01177):1类创新药罗伐昔替尼片“Rovadicitinib(TQ05105)”新药上市申请获得受理
中国生物制药(01177)下跌5.19%,报2.74元/股
金融界 · 07-15
中国生物制药(01177)下跌5.19%,报2.74元/股
中国生物制药盘中异动 股价大跌5.19%报2.741港元
自选股智能写手 · 07-15
中国生物制药盘中异动 股价大跌5.19%报2.741港元
中国生物制药(01177)股价下跌5.19%,现价港币$2.74
阿斯达克财经 · 07-15
中国生物制药(01177)股价下跌5.19%,现价港币$2.74
暂无数据
公司概况
公司名称:
中国生物制药
所属市场:
SEHK
上市日期:
--
主营业务:
中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。
发行价格:
--
{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":2.89,"timestamp":1721635736027,"preClose":2.85,"halted":0,"volume":18653784,"delay":0,"floatShares":18791217230,"shares":18791217230,"eps":0.13475232,"marketStatus":"已收盘","marketStatusCode":5,"change":0.04,"latestTime":"07-22 16:08:56","open":2.86,"high":2.9,"low":2.84,"amount":53688963,"amplitude":0.021053,"askPrice":2.89,"askSize":116000,"bidPrice":2.88,"bidSize":1293000,"shortable":3,"etf":0,"ttmEps":0.13475231232872434,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":2.85,"dividendRate":0.016835,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":0.417883,"impliedVol":0.4171,"impliedVolPercentile":0.5182,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK"},"requestUrl":"/m/hq/s/01177/tweets","defaultTab":"tweets","newsList":[{"id":"2453755696","title":"中国生物制药07月22日主力资金流入854万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2453755696","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453755696?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:16","pubTimestamp":1721636175,"startTime":"0","endTime":"0","summary":"07月22日, 中国生物制药股价涨1.40%,报收2.89元,成交金额5368万元,换手率0.10%,振幅2.11%,量比0.42。中国生物制药今日主力资金净流入854万元,连续5日净流入,上一交易日主力净流入952万元,今日环比减少10.29%。该股近5个交易日上涨3.99%,主力资金累计净流入1.05亿元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入1.23亿元,其中净流入天数为11日。该股主力净额占比0.02%,港股市场排名154/2647。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072216163295e79b26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072216163295e79b26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1589","01177","BK1521"],"gpt_icon":0},{"id":"2452884442","title":"【港股通】中国生物制药(01177)ESG表现获标普全球、富时罗素等多家权威机构认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2452884442","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452884442?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:50","pubTimestamp":1721379030,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药(01177)公告,凭借持续且稳定的环境、社会及企业管治(ESG)实践表现,集团已获得标普全球(S&P Global)、富时罗素(FTSE Russell)等多家全球可持续发展权威机构的认可。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MDI5YWZjNTM0NzAzOGFlZTg0NjQ3Mjg2ZTU5YjgxNDI5NDY5NzkxMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MDI5YWZjNTM0NzAzOGFlZTg0NjQ3Mjg2ZTU5YjgxNDI5NDY5NzkxMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940742","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IWO","YANG","RWM","SG9999018857.SGD","IE00B19Z9505.USD","LU0868494617.USD","SG9999014906.USD","SG9999017495.SGD","LU0342679015.USD","LU1989763005.USD","IWN","UWM","GB00BDT5M118.USD","LU2089284900.SGD","LU2264538146.SGD","HSCEI","LU2089283258.USD","SG9999014880.SGD","BK4588","SRTY","BK4585","LU0354030511.USD","07226","SPGI","LU1989764748.USD","TZA","159717","LU1804176565.USD","SGXZ31699556.SGD","LU2111349929.HKD","TWM","BK4581","HSTECH","LU1988902786.USD","LU2028103732.USD","SG9999014914.USD","LU1633808545.USD","IWM","MRTYmain","LU1989764664.SGD","LU2023251221.USD","01177","LU0354030438.USD","LU1989773731.SGD","MNQmain","TNA","LU1989772923.USD","BK1191","ESG","LU1989772840.SGD"],"gpt_icon":0},{"id":"2452441380","title":"中国生物制药(01177.HK):ESG表现获得标普全球、富时罗素认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2452441380","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452441380?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:35","pubTimestamp":1721378152,"startTime":"0","endTime":"0","summary":"格隆汇7月19日丨中国生物制药宣布,集团凭借持续且稳定的环境、社会及企业管治实践表现,已获得标普全球、富时罗素等多家全球可持续发展权威机构的认可。CSA是全球规模最大的企业可持续发展实践年度评估之一。目前,集团CSA评分已稳步提升至55分,超过全球92%的同业企业,处于国际领先水平。集团首次入选FTSE4Good指数并连续第二年入选标普全球《可持续发展年鉴(中国版)》,代表着国际资本市场专业机构对集团ESG实践表现的持续、高度认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071916360595dba3b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071916360595dba3b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TWM","LU2028103732.USD","LU0971096721.USD","LU1988902786.USD","MRTYmain","SG9999018857.SGD","IE00B19Z9505.USD","BK4585","LU2264538146.SGD","UWM","LU2089283258.USD","ESG","MNQmain","SG9999014898.SGD","BK4548","LU2210150020.SGD","LU1496350502.SGD","LU2089284900.SGD","TZA","LU2210149790.SGD","BK4535","TNA","LU1989773731.SGD","LU1064131342.USD","LU1989763005.USD","LU1989764664.SGD","SPGI","BK4588","BK4534","RWM","LU0868494617.USD","IWN","01177","LU1989764748.USD","LU1989772840.SGD","GB00BDT5M118.USD","SG9999018865.SGD","IWO","LU0354030511.USD","LU0158827781.USD","BK4581","SGXZ31699556.SGD","LU2271345857.HKD","IWM","LU0354030438.USD","LU1989772923.USD","SG9999001077.SGD","LU0158827948.USD","LU1633808545.USD","SRTY","SG9999014880.SGD"],"gpt_icon":0},{"id":"2452437993","title":"中国生物制药(01177.HK)1类创新药库莫西利胶囊的新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452437993","media":"港股解码","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452437993?lang=zh_cn&edition=full","pubTime":"2024-07-18 17:31","pubTimestamp":1721295084,"startTime":"0","endTime":"0","summary":"【财华社讯】中国生物制药(01177.HK)公布,集团开发的1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”联合氟维司群注射液用于既往内分泌经治的激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌的III期临床试验(NCT05375461)已完成期中分析,经独立数据监查委员会(IDMC)审核,达到预设的主要终点,...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OnJC5UF9P_vW-bZGFGxgPFTrnmv2NCCrb5v4iKJVUcxBcAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OnJC5UF9P_vW-bZGFGxgPFTrnmv2NCCrb5v4iKJVUcxBcAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240718A07I4500","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240718A07I4500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["06978","BK1574","BK1515","BK1191","BK1589","01177","BK1161","BK1521"],"gpt_icon":0},{"id":"2452172541","title":"中国生物制药(01177):1类创新药库莫西利胶囊“Culmerciclib(TQB3616)”新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452172541","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452172541?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:36","pubTimestamp":1721291768,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药 发布公告,集团开发的1类创新药库莫西利胶囊“Culmerciclib”联合氟维司群注射液用于既往内分泌经治的激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌的III期临床试验已完成期中分析,经独立数据监查委员会审核,达到预设的主要终点,研究结果将在学术期刊或重大学术会议上予以公布。集团已向中国国家药品监督管理局药品审评中心递交新药上市申请并获受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","BK1515","BK1521","BK1574","BK1589","06978","BK1161","BK1191","159992"],"gpt_icon":0},{"id":"2452017156","title":"中国生物制药07月18日主力资金流入1901万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452017156","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452017156?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:15","pubTimestamp":1721290520,"startTime":"0","endTime":"0","summary":"07月18日, 中国生物制药股价涨0.34%,报收2.96元,成交金额1.23亿元,换手率0.22%,振幅2.37%,量比0.90。中国生物制药今日主力资金净流入1901万元,连续3日净流入,上一交易日主力净流入3675万元,今日环比减少48.27%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为33.33%,平均涨幅为2.04%。该股近5个交易日上涨4.59%,主力资金累计净流入1.03亿元;近20日主力资金累计净流入6336万元,其中净流入天数为9日。该股主力净额占比0.03%,港股市场排名98/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071816153295d42bee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071816153295d42bee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1589","BK1515","01177","BK1191"],"gpt_icon":0},{"id":"2452186397","title":"中国生物制药(01177)出现大手买入200万股,成交价$2.95,涉资590万","url":"https://stock-news.laohu8.com/highlight/detail?id=2452186397","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452186397?lang=zh_cn&edition=full","pubTime":"2024-07-17 15:03","pubTimestamp":1721199780,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午03:03出现大手买入,成交量为200万,成交价为港币$2.95,涉资590万。至目前为止,股价升4.255%,今日最高价为$2.97,而最低价为$2.81,总成交量为5.498千万股,总成交金额港币$1.602亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2407174129/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1589","BK1515","01177","BK1521"],"gpt_icon":0},{"id":"2452554907","title":"中国生物制药(01177)上涨5.32%,报2.97元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452554907","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452554907?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:51","pubTimestamp":1721195460,"startTime":"0","endTime":"0","summary":"7月17日,中国生物制药(01177)盘中上涨5.32%,截至13:51,报2.97元/股,成交1.27亿元。中国生物制药有限公司是一家以创新研究和研发驱动的医药集团,主营业务涵盖医药研发、智能化生产和销售,产品在肿瘤、肝病、呼吸系统、外科/镇痛等领域具有优势。公司在全球制药企业中具有显著地位,连续五年入选全球制药企业TOP50,且在股市表现上也有显著成绩,如入选恒生指数成分股和恒生中国企业指数成分股等。截至2023年年报,中国生物制药营业总收入261.99亿元、净利润23.32亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/17135141615771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1521","BK1589","BK1515","01177","BK1191"],"gpt_icon":0},{"id":"2452690034","title":"中国生物制药盘中异动 急速拉升5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452690034","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452690034?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:50","pubTimestamp":1721195456,"startTime":"0","endTime":"0","summary":"2024年07月17日下午盘13时50分,中国生物制药股票出现波动,股价急速拉升5.32%。中国生物制药股票所在的药品行业中,整体涨幅为0.48%。该信息摘要如下:中国生物制药有限公司近日宣布,其自主研发的1类创新药盐酸安罗替尼胶囊在联合化疗用于晚期不可切除或转移性软组织肉瘤一线治疗的III期临床研究中,已达到主要研究终点无进展生存期的优效界值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717135057af92b442&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717135057af92b442&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1589","BK1515","BK1191","BK1521"],"gpt_icon":0},{"id":"2452990216","title":"港股异动 | 中国生物制药(01177)涨近5% 创新产品正密集上市 上半年业绩增速复苏确定性高","url":"https://stock-news.laohu8.com/highlight/detail?id=2452990216","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452990216?lang=zh_cn&edition=full","pubTime":"2024-07-17 13:36","pubTimestamp":1721194607,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中国生物制药涨近5%,截至发稿,涨4.96%,报2.96港元,成交额1.21亿港元。公司表示将于于近期递交上市申请。交银国际指出,公司1H24业绩增速复苏确定性高,该行预计收入和净利润增长均在10%以上,主要得益于肿瘤领域新产品销售的持续放量,以及外科领域核心品种持续的强劲增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071713445495ccb3e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071713445495ccb3e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSCEI","BK1521","01177","BK1589","HSTECH","BK1515","BK1191"],"gpt_icon":1},{"id":"2451950993","title":"中国生物制药(01177):盐酸安罗替尼胶囊联合化疗用于晚期软组织肉瘤一线治疗III期研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2451950993","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451950993?lang=zh_cn&edition=full","pubTime":"2024-07-16 16:33","pubTimestamp":1721118804,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)发布公告,该集团自主研发的1类创新药盐酸安罗替尼胶囊联合...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4134","BK1521","BK1515","01177","BK1589","BK1191","III"],"gpt_icon":0},{"id":"2451959893","title":"中国生物制药(01177)出现大手买入75.2万股,成交价$2.82,涉资212.064万","url":"https://stock-news.laohu8.com/highlight/detail?id=2451959893","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451959893?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:02","pubTimestamp":1721113320,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在下午03:02出现大手买入,成交量为75.2万,成交价为港币$2.82,涉资212.064万。至目前为止,股价升1.812%,今日最高价为$2.83,而最低价为$2.72,总成交量为3.224千万股,总成交金额港币$9.019千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2407165284/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1521","BK1589","01177","BK1515"],"gpt_icon":0},{"id":"2451930161","title":"【港股通】中国生物制药(01177)反复涨超2% 交银指其上半年业绩增速复苏确定性高","url":"https://stock-news.laohu8.com/highlight/detail?id=2451930161","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451930161?lang=zh_cn&edition=full","pubTime":"2024-07-16 14:03","pubTimestamp":1721109811,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药 股价反复扬升,截至发稿,涨2.17%,报2.82港元,成交额6939.06万港元。集团已向中国国家药品监督管理局药品审评中心递交新药上市申请并获受理。交银国际发研指,公司1H24业绩增速复苏确定性高,该行预计收入和净利润增长均在10%以上,主要得益于肿瘤领域新产品销售的持续放量,以及外科领域核心品种持续的强劲增长。重申公司“买入”评级,上调2024-26年净利润预测2%-3%,以反映更强的业绩增速复苏能见度,目标价4.8港元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTc5ODJhYWQ2MDcxZDU1Zjc2OTIwMzU3MzY2MTU5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940471","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1515","07226","HSTECH","YANG","HSCEI","BK1191","BK1521","01177"],"gpt_icon":0},{"id":"2451939851","title":"中国生物制药(01177)出现大手买入96.8万股,成交价$2.81,涉资272.008万","url":"https://stock-news.laohu8.com/highlight/detail?id=2451939851","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451939851?lang=zh_cn&edition=full","pubTime":"2024-07-16 11:55","pubTimestamp":1721102100,"startTime":"0","endTime":"0","summary":"[大手成交]中国生物制药(01177)在上午11:55出现大手买入,成交量为96.8万,成交价为港币$2.81,涉资272.008万。至目前为止,股价升1.449%,今日最高价为$2.82,而最低价为$2.72,总成交量为2.085千万股,总成交金额港币$5.816千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145552499_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2407164816/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1191","BK1589","01177","BK1521"],"gpt_icon":0},{"id":"2451660719","title":"智通港股早知道 | 美联储对通胀达标的信心有所增强 TCL电子(01070)发盈喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2451660719","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451660719?lang=zh_cn&edition=full","pubTime":"2024-07-16 07:42","pubTimestamp":1721086923,"startTime":"0","endTime":"0","summary":"鲍威尔:近期经济数据令美联储对通胀达标的信心有所增强美联储主席鲍威尔表示,第二季度经济数据让决策者对通胀可持续的向2%目标迈进变得更有信心。其中一季度出货量40GWh,二季度出货量76GWh。总载货量上升0.9%,运载力下降3.4%。整体运载率较2023年同期上升3.6%,每个标准箱之整体平均收入较去年第2季度增加13.4%。截至2024年6月30日止首6个月之总收入及总载货量较去年同期分别增加2.2%及2.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","BK4559","BK1515","BK1546","ESmain","BK1103","BK4534","BK1116","BK1557","BK4588","SPY","UPRO","BK4550","IVV","BK4581","SDS","SSO","OEF","01133","BK1521","01729","OEX","HSTECH","01070","BK4504",".SPX","BK1096","SH","HSCEI","01177","BK1205","07226","BK1589","BK4585","00316","SPXU","BK1191"],"gpt_icon":0},{"id":"2451454616","title":"中生制药(01177.HK)创新药罗伐昔替尼片获国家药监局受理新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2451454616","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451454616?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:01","pubTimestamp":1721034060,"startTime":"0","endTime":"0","summary":"中国生物制药公布,集团开发的1类创新药罗伐昔替尼片“Rovadicitinib”用于治疗中高危骨髓纤维化的关键注册临床试验已完成最终分析,达到主要终点。集团已向国家药品监督管理局药品审评中心递交新药上市申请并获受理。该药物是集团自主研发的一款具有全新化学结构的JAK/ROCK抑制剂,能够有效抑制JAK家族激酶活性及ROCK激酶活性,显著抑制细胞中STAT3和STAT5的磷酸化水平,从而抑制JAK/STAT信号通路传导作用,进而发挥抗肿瘤活性。沽空资料截至 2024-07-15 16:25。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1363711/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01477","06978","BK1574","BK1191","BK1515","BK1589","01177","BK1161","BK1521","159992"],"gpt_icon":0},{"id":"2451961650","title":"中国生物制药(01177):1类创新药罗伐昔替尼片“Rovadicitinib(TQ05105)”新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451961650","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451961650?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:00","pubTimestamp":1721034010,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药 发布公告,集团开发的1类创新药罗伐昔替尼片“Rovadicitinib ”用于治疗中高危骨髓纤维化的关键注册临床试验已完成最终分析,达到主要终点。集团已向中国国家药品监督管理局药品审评中心递交新药上市申请并获受理。罗伐昔替尼片是集团近期申报上市的又一款1类创新药。集团正加速推进罗伐昔替尼片的多项临床研究,充分挖掘其临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01177","159992","BK1515","BK1191","BK1589","06978","BK1574","BK1161","BK1521"],"gpt_icon":0},{"id":"2451099692","title":"中国生物制药(01177)下跌5.19%,报2.74元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451099692","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451099692?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:32","pubTimestamp":1721028778,"startTime":"0","endTime":"0","summary":"7月15日,中国生物制药(01177)盘中下跌5.19%,截至15:32,报2.74元/股,成交8570.35万元。中国生物制药有限公司是一家以创新研究和研发驱动的医药集团,主营业务涵盖医药研发、智能化生产和销售,产品在肿瘤、肝病、呼吸系统、外科/镇痛等领域具有优势。公司在全球制药企业中具有显著地位,连续五年入选全球制药企业TOP50,且在股市表现上也有显著成绩,如入选恒生指数成分股和恒生中国企业指数成分股等。截至2023年年报,中国生物制药营业总收入261.99亿元、净利润23.32亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/15153241569696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1521","BK1515","BK1191","BK1589","01177"],"gpt_icon":0},{"id":"2451924046","title":"中国生物制药盘中异动 股价大跌5.19%报2.741港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451924046","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451924046?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:32","pubTimestamp":1721028775,"startTime":"0","endTime":"0","summary":"2024年07月15日临近收盘15时32分,中国生物制药股票出现波动,股价急速跳水5.19%。截至发稿,该股报2.741港元/股,成交量3072.55万股,换手率0.16%,振幅5.19%。资金方面,该股资金流入2720.23万港元,流出5263.54万港元。中国生物制药股票所在的药品行业中,整体跌幅为0.37%。消息层面,截至15时32分,《交银国际:重申中国生物制药“买入”评级 目标价4.8港元》资讯为影响中国生物制药的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715153255941f704f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240715153255941f704f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1515","BK1521","BK1589","BK1191"],"gpt_icon":0},{"id":"2451697213","title":"中国生物制药(01177)股价下跌5.19%,现价港币$2.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2451697213","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451697213?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:32","pubTimestamp":1721028720,"startTime":"0","endTime":"0","summary":"[下跌股]中国生物制药(01177) 股价在下午03:32比前收市价下跌5.19%,现股价为港币$2.74。至目前为止,今日最高价为$2.89,而最低价为$2.74。总成交量为3.071千万股,总成交金额为港币$8.567千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407152033/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1521","BK1515","BK1191","BK1589","01177"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.2311},{"period":"6month","weight":-0.0169},{"period":"1year","weight":-0.1541},{"period":"ytd","weight":-0.1698}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事药品业务的投资控股公司。该公司通过三个业务分部进行运营。中药现代制剂及西药分部从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部从事长期及短期投资业务。其他分部主要从事研发活动、向第三方提供服务以及从事相关医疗及医院业务。该公司还通过其子公司从事持有物业、销售健康食品、验光配镜以及零售与批发视光和听力产品业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.011037},{"month":2,"riseRate":0.666667,"avgChangeRate":0.059327},{"month":3,"riseRate":0.571429,"avgChangeRate":0.043253},{"month":4,"riseRate":0.47619,"avgChangeRate":0.025756},{"month":5,"riseRate":0.714286,"avgChangeRate":0.038694},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000536},{"month":7,"riseRate":0.619048,"avgChangeRate":0.030891},{"month":8,"riseRate":0.35,"avgChangeRate":-0.022888},{"month":9,"riseRate":0.35,"avgChangeRate":-0.024794},{"month":10,"riseRate":0.6,"avgChangeRate":0.037036},{"month":11,"riseRate":0.55,"avgChangeRate":0.076835},{"month":12,"riseRate":0.45,"avgChangeRate":-0.006547}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}